Physician profile
John D Randall
NPI 1033199914
$3,051.29
in general payments reported to CMS, 2019-2025
21 companies · $653 in 2025
The $653 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $393 · 2021: $224 · 2022: $306 · 2023: $643 · 2024: $659 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,956.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,955.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $537.92 | 2022-2024 | |
| Alcon Vision LLC | $453.06 | 2019-2025 | Total30, Tryptyr, Precision7 |
| Sun Pharmaceutical Industries INC. | $349.06 | 2020-2024 | |
| Johnson & Johnson Vision Care, INC. | $268.77 | 2019-2025 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $242.42 | 2024-2025 | Xdemvy |
| Allergan, INC. | $213.31 | 2020-2022 | |
| Horizon Therapeutics Plc | $124.99 | 2023 | Tepezza |
| Coopervision INC. | $113.87 | 2019 | |
| Mallinckrodt Hospital Products INC. | $111.74 | 2025 | Acthar |
| Sight Sciences, INC. | $102.99 | 2023 | Omni Surgical System |
| Lkc Technologies, INC. | $97.65 | 2025 | |
| Novartis Pharmaceuticals Corporation | $92.61 | 2021 | |
| Rxsight INC | $78.95 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Bausch & Lomb Americas INC. | $73.14 | 2023-2025 | Infuse, Vyzulta, Biotrue One Day |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $53.75 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $41.76 | 2025 | Iolmaster 700 |
| Oyster Point Pharma, INC. | $33.84 | 2022-2023 | Tyrvaya |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Harrow Eye, LLC | $17.47 | 2024 | Vevye |
| Kala Pharmaceuticals, INC. | $12.61 | 2021 | |
| Shire North American Group INC | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Randall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.